Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janine Schuurman

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Immunology|February 19, 2002
IgG4 breaking the rulesRob C Aalberse, Janine Schuurman
Current Opinion in Immunology|April 17, 2016
Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?Janine Schuurman, Paul Whi Parren
Methods (San Diego, Calif.)|November 5, 2013
Mind the gapJanine Schuurman, Paul W H I Parren
Current Opinion in Immunology|June 26, 2008
When binding is enough: nonactivating antibody formatsAran F Labrijn, Rob C Aalberse, Janine Schuurman
Mabs|September 8, 2012
Fab-arm exchange: what's in a name?Janine Schuurman, Aran F Labrijn, Paul W H I Parren
Nature Reviews. Drug Discovery|July 5, 2022
Avidity in antibody effector functions and biotherapeutic drug designSimone C Oostindie, Greg A Lazar, Janine Schuurman, et al.
Cancers|January 20, 2021
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid TumorsJim Middelburg, Kristel Kemper, Patrick Engelberts, et al.
Mabs|May 3, 2014
Opening the door to innovationJanine Schuurman, Yvo F Graus, Aran F Labrijn, et al.
Infection and Immunity|December 11, 2019
Bypassing Phase Variation of Lipooligosaccharide (LOS): Using Heptose 1 Glycan Mutants To Establish Widespread Efficacy of Gonococcal Anti-LOS Monoclonal Antibody 2C7Srinjoy Chakraborti, Sunita Gulati, Bo Zheng, et al.
Immunology and Cell Biology|March 30, 2023
Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activityAlicia M Chenoweth, Sandra Esparon, Bruce D Wines, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Immunology|February 19, 2002
IgG4 breaking the rulesRob C Aalberse, Janine Schuurman
Current Opinion in Immunology|April 17, 2016
Editorial overview: Special section: New concepts in antibody therapeutics: What's in store for antibody therapy?Janine Schuurman, Paul Whi Parren
Methods (San Diego, Calif.)|November 5, 2013
Mind the gapJanine Schuurman, Paul W H I Parren
Current Opinion in Immunology|June 26, 2008
When binding is enough: nonactivating antibody formatsAran F Labrijn, Rob C Aalberse, Janine Schuurman
Mabs|September 8, 2012
Fab-arm exchange: what's in a name?Janine Schuurman, Aran F Labrijn, Paul W H I Parren
Nature Reviews. Drug Discovery|July 5, 2022
Avidity in antibody effector functions and biotherapeutic drug designSimone C Oostindie, Greg A Lazar, Janine Schuurman, et al.
Cancers|January 20, 2021
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid TumorsJim Middelburg, Kristel Kemper, Patrick Engelberts, et al.
Mabs|May 3, 2014
Opening the door to innovationJanine Schuurman, Yvo F Graus, Aran F Labrijn, et al.
Infection and Immunity|December 11, 2019
Bypassing Phase Variation of Lipooligosaccharide (LOS): Using Heptose 1 Glycan Mutants To Establish Widespread Efficacy of Gonococcal Anti-LOS Monoclonal Antibody 2C7Srinjoy Chakraborti, Sunita Gulati, Bo Zheng, et al.
Immunology and Cell Biology|March 30, 2023
Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activityAlicia M Chenoweth, Sandra Esparon, Bruce D Wines, et al.
Pageof 8